Business
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2025 which ended March 31, 2025.The Company's full financial statements and related MD&A for the third quarter ended March 31, 2025, are available
About this update from Inmed Pharmaceuticals Inc.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2025 which ended March 31, 2025.","length":405,"tagName":"p"},{"type":"text","content":"The Company's full financial statements and related MD&A for the third quarter ended March 31, 2025, are available at www.inmedpharma.com, www.sedarplus.com and at www.sec.gov.","length":184,"tagName":"p"},{"type":"text","content":"Eric A. Adams, InMed's Chief Executive Officer, commented, "We continue to advance INM-901 as a differentiated approach to treating Alzheimer's disease by targeting neuroinflammation beyond conventional amyloid beta and tau-targeting strategies, and we look forward to sharing additional data in the near term."","length":329,"tagName":"p"},{"type":"text","content":"Adams continued, "On the commercial side, BayMedica continues to deliver stable revenues quarter-over-quarter. While gross margins were impacted by increased pricing pressure, we remain focused on optimizing our product mix and improving operational efficiencies."","length":274,"tagName":"p"},{"type":"text","content":"Business Update - Pharmaceutical Development Programs","length":53,"tagName":"p"},{"type":"text","content":"INM-901: Targeting multiple biological pathways in Alzheimer's disease ('AD')INM-901 is a proprietary small molecule drug candidate currently under development for the treatment of Alzheimer's disease (AD), with multiple mechanisms of action.","length":259,"tagName":"p"},{"type":"text","content":"Positive data from long-term in vivo preclinical AD studies highlighted INM-901's ability to significantly reduce neuroinflammation - a key factor in the onset and progression of Alzheimer's disease. The Company is currently conducting further research examining INM-901's impact on neuroinflammation independent of amyloid beta plaques and tau protein tangles which are the primary targets of conventional therapies.","length":429,"tagName":"p"},{"type":"text","content":"Additionally, analyses from this long-term stud...